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Foreword
Open access publishing has the potential to revolutionise 
the way in which biomedical scientists publish and access 
the latest results in their field. There are opportunities to 
accelerate the use of open access but there are also hurdles 
to its widespread uptake.
Over the past few months, various reports and 
communications have been published on the topic of open 
access. These include the Finch Group report on 18 June 
2012, the Publishing and the Ecology of European Research 
(PEER) final report on 19 June 2012, the European Research 
Council (ERC) announcement of its new open access policy 
on 13 July 2012, and the European Commission’s launch 
of a communication and recommendations to Member 
States ‘Towards better access to scientific information’ on 
17 July 2012. On the same day, Science Europe reaffirmed 
its commitment to strengthening the European Research 
Area and recognised open access as a priority area in which 
a common policy and action plan will be developed and 
implemented. This intensive period shows the timeliness of 
our publication.
In recognition of the importance of open access to 
the biomedical sciences, the European Medical Research 
Councils (EMRC) of the European Science Foundation 
(ESF), at the instigation of its Core Group member Professor 
Josef Syka of the Czech Science Foundation and the 
Academy of Sciences of the Czech Republic (GAČR and 
AVČR), launched an activity to investigate what, if any, steps 
EMRC could usefully take to improve the open access 
landscape in the biomedical field across Europe. EMRC 
task force meetings held in September and November 
2011 led to the identification of a number of issues and the 
drafting of a preliminary document. These issues included 
the coexistence between open access and the traditional 
business model of scientific publishers (including scientific 
learned societies), the recognised challenges associated 
with researchers understanding the concept of open 
access and depositing their research in local repositories, 
the recognition of PubMed Central (PMC) as a model of 
disciplinary repository in the biomedical field, and the 
desirability and/or feasibility of expanding UK PubMed 
Central (UKPMC) to include more European biomedical 
research outputs. While this report was in preparation, 
the ERC joined UKPMC and funders agreed to rename it 
‘Europe PMC’ as of November 2012.
An expert group meeting took place in Madrid on 
21-22 March 2012 hosted by the Spanish ‘Consejo 
Superior de Investigaciones Científicas’ (CSIC), one of the 
task force member organisations. Participants included 
publishers (Elsevier, BioMed Central, Public Library of 
Science), the European Commission, nominated experts 
from 12 ESF Member Organisations (including the task 
force members) and other research performing/funding 
organisations, foundations or charities, including the 
Spanish Foundation for Science and Technology (FECYT), 
ES; the Spanish National Health Institute Carlos III (ISCIII), 
ES; the Wellcome Trust, UK; the Academy of Sciences, 
CZ; the National Institute of Health (ISS), IT; and the 
Foundation for National Scientific Computing (FCCN), PT. 
Other participants included open access experts from 
the Research Information Network (RIN), the Scholarly 
Publishing and Academic Resources Coalition (SPARC) 
Europe, the Association of European Research Libraries 
(LIBER), the European Association for Cancer Research 
(EACR) and Knowledge Exchange, as well as experts 
from several European infrastructures, including the 
European Organization for Nuclear Research (CERN) and 
the European Molecular Biology Laboratory - European 
Bioinformatics Institute (EMBL-EBI). The many valuable 
inputs from participants made it clear that the current model 
for accessing biomedical research is far from ideal and that 
all research stakeholders (funding agencies, publishers, 
research performing institutions, research libraries and 
learned societies) need to work together to shift to an open 
access model in the field. However, a number of potential 
hurdles, discussed in this briefing, remain to be overcome.
Finally, we would like to thank the Science Policy Briefing 
Chair, Professor Syka, the task force, the expert group 
members and the ESF-EMRC staff – all listed at the end of 
the publication – for their excellent work.
Professor Liselotte Højgaard
EMRC Chair
Professor Pär Omling
ESF President and Science Europe Vice-President
© Clover / SuperStock
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Introduction
The Internet and technological developments that 
have arisen from it in recent years have the potential 
to radically change science publishing and maximise 
the impact of research in a way that was not possible 
or even envisioned when publishing was a subscription- 
and paper-based process. We envisage a full open access 
future – one in which all published research generated 
by science researchers in the European Union (EU) is 
immediately available online in human and machine 
readable form, published under a license that allows 
unlimited re-use while ensuring authors’ rights of attri-
bution, and with secure automatic archiving in publicly 
run databases.
The concept is not new: the 2002 Budapest Open 
Access Initiative1 and the Bethesda Statement on Open 
Access Publishing2, which was agreed on in 2003 by 
the biomedical research community, discussed how to 
provide open access to primary scientific literature as 
rapidly as possible. The Berlin Declaration on Open 
Access to Knowledge in the Sciences and Humanities 
was also published in 20033. A definition is provided 
in Box 1.
A successful model for the future will maximise the 
value of research investments by:
•	increasing	access	to	the	results	of	research	undertaken	
in Europe, preferably so that everyone in the world has 
free access at the point of use to all the published out-
puts of research;
•	increasing	access	in	Europe	to	the	global	outputs	of	
research;
•	ensuring	that	the	published	outputs	of	research	are	
subject to effective quality assurance through peer 
review;
•	ensuring	 that	 the	 scholarly	 communication	 system	
develops in a sustainable way and operates cost-effec-
tively; and
•	ensuring	the	long-term	preservation	of	the	records	of	
science.
The objective of this ESF-EMRC Science Policy Briefing 
is to accelerate the adoption of open access in order to 
guarantee equitable access to European biomedical 
research outputs worldwide. In this document, the term 
‘research outputs’ refers to research publications (journal 
articles and conference papers4), mostly generated from 
1. www.soros.org/openaccess/read
2. www.earlham.edu/~peters/fos/bethesda.htm
3. http://oa.mpg.de/lang/en-uk/berlin-prozess/berliner-erklarung/
4.	Research	Information	Network	(RIN),	Publishing	Research	
Executive summary
This Science Policy Briefing 
aims to accelerate the adop-
tion of open access to research 
articles in the biomedical sci-
ences. Open access refers to 
the free availability on the 
public Internet of scholarly 
articles published in an elec-
tronic format, permitting any 
user to read and re-use the 
content provided only that the 
author	 is	 properly	 acknowl-
edged and cited. We consider 
open access to be crucial for 
the free flow of information 
between researchers and within society as a whole, and 
the digital revolution of recent years provides an oppor-
tunity that has not yet been fully realised to transform 
access to scholarly publications. To achieve this goal this 
briefing	makes	a	number	of	recommendations:	
1.  There is a moral imperative for open access: research 
papers should be made freely available to all to read, 
use	 and	 re-use,	 with	 appropriate	 acknowledge-
ment, in order to maximise the value of biomedical 
research,	build	on	the	body	of	knowledge,	accelerate	
the process of discovery and improve human health.
2.		 Individual	 agencies	 must	 work	 together	 to	 raise	
awareness of the moral imperative for open access: 
agencies and organisations that fund and perform 
research, libraries, publishers and researchers must 
work	 in	 concert	 to	 raise	 awareness	 of	 the	moral	
imperative for open access publishing. National, 
European and international partnerships are the 
basis for the successful achievement of open access 
to research outputs. Specific actions that different 
agencies	need	to	undertake	in	order	to	move	towards	
this goal are outlined in this briefing.
3.		 All	research	stakeholders	should	work	together	to	
support the extension of Europe PubMed Central 
into a Europe-wide PubMed Central: in order to 
facilitate discoveries and innovation in biomedical 
research,	research	stakeholders	should	collaborate	to	
establish a Europe-wide repository in biomedicine as 
a partner site to the US equivalent PubMed Central. 
The recently rebranded Europe PubMed Central 
represents a valuable means to achieving this goal, 
provided that the diversity of European partner man-
dates and policies can be integrated.
Hippocratic Oath 
“I swear […] to give a share of 
precepts and oral instruction 
and all the other learning to my 
sons and to the sons of him 
who has instructed me”
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Science (PLoS8) and BioMed Central (BMC9) fully 
operate on this model. Several universities, research 
institutions and research funders10 support the gold 
route, which means that authors in these institu-
tions either publish in open access journals or pay 
publication charges (funded by the research funder 
or	an	institutional	open	access	fund)	to	make	their	
article available in open access. Gold open access 
journals do not charge readers and grant extensive 
usage rights in accordance with the Budapest Open 
Access Initiative definition. 
Box 3. The green route
The green route (also known as self-archiving) 
involves researchers depositing in an institutional or 
subject-based repository, subject to copyright/license 
permissions11, copies of the articles they publish, 
whether in an open access or a traditional journal 
that requires a subscription from readers or their 
libraries. The repository will then make those copies 
available to the public, either immediately upon pub-
lication or after an embargo period. 
The embargo duration is correlated to the read-
ership ‘half-life’ of biomedical papers, which is 
typically 6-12 months (vs. 24 for science and technol-
ogy and 36 for arts and humanities12). The embargo 
ensures the continued value of subscriptions for 
commercially published journals. Advocates of 
open	access	would	like	to	keep	this	period	as	short	
as possible. The rate at which accepted manuscripts 
are deposited in institutional and discipline-based 
repositories is driven by the enforcement of man-
dates by funders and/or institutions. 
8. www.plos.org
9. www.biomedcentral.com
10. Funders: research funding organisations, charities, philanthropic 
associations, governments, etc.
11. For example, Elsevier’s conditions of use: http://libraryconnect.
elsevier.com/newsletters/supporting-usersorganizations/2011-04/ways-
use-journal-articles-published-elsevier
12. RIN, JISC, Research Libraries UK, PRC and the Wellcome Trust 
joint report. Heading for the open road: costs and benefits of transitions in 
scholarly communications (2011). http://rinarchive.jisc-collections.ac.uk/
our-work/communicating-and-disseminating-research/heading-open-
road-costs-and-benefits-transitions-s 
public funding, and not to research data (genomics, pro-
tein,	gene	data,	etc.)	or	books.
Researchers	 can	currently	make	 their	work	 freely	
available through two main mechanisms: the gold route 
(Box 2) and the green route (Box 3). The two mecha-
nisms coexist and are complementary. The controversial 
hybrid model will not be the focus of this briefing, 
although it is an important element to mention5. 
Box 1. Definition of open access
The Budapest Open Access Initiative defines 
open access pertaining to scientific and scholarly 
research articles as follows: “By ‘open access’ to this 
literature, we mean its free availability on the pub-
lic Internet, permitting any users to read, download, 
copy, distribute, print, search, or link to the full texts 
of these articles, crawl them for indexing, pass them 
as data to software, or use them for any other lawful 
purpose, without financial, legal, or technical barri-
ers other than those inseparable from gaining access to 
the Internet itself. The only constraint on reproduc-
tion and distribution, and the only role for copyright 
in this domain, should be to give authors control over 
the integrity of their work and the right to be properly 
acknowledged and cited.”
Box 2. The gold route
Through the gold route researchers publish their 
articles in journals that offer open access publishing 
by making articles available free of charge to read-
ers immediately upon publication, usually in return 
for the payment of an article processing charge by the 
author.
Gold open access includes the secure archiv-
ing of articles in publicly available archives such as 
PubMed Central (PMC)6 or UKPMC7. Some jour-
nals such as those published by the Public Library of
•••
Consortium (PRC) and Joint Information Systems Committee (JISC) 
report. Access to scholarly content: gaps and barriers (2011). http://
rinarchive.jisc-collections.ac.uk/node/1172.	A	key	finding	of	this	report	
stresses that journal articles and conference papers are critical for 
advanced research and scholarship and are rated as ‘important’ by 90.4% 
and 58.2% of survey respondents, respectively.
5. The hybrid model is often criticised as publishers receive income from 
subscriptions and from article processing charges for the same journals.
6. www.ncbi.nlm.nih.gov/pmc 
7.	http://ukpmc.ac.uk/ and McEntyre J et al. UKPMC: a full text article 
resource for the life sciences. Nucleic Acids Res. 39: D58-65 (2011).  
http://ukpmc.ac.uk/articles/PMC3013671
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We need to find new ways of facilitating and acceler-
ating	knowledge	sharing	and	new	discovery	potential,	
not only to improve human health but also to promote 
economic growth. Ultimately what is needed is easy, 
immediate free access to literature, for use and re-use, 
for both humans and machines. EMRC supports the 
gold route to open access publishing as the ultimate goal 
to maximise the discoverability, access and re-use of 
biomedical research in Europe, wherever it is funded or 
performed, but under the condition that article process-
ing charges (APCs) are affordable and sustainable. 
Whilst there is evidence of tremendous growth in 
open access publishing in the last 10 years13 (Figure 1), a 
recent editorial calculated that at a projected 20% annual 
growth,	only	about	27%	of	papers	will	be	published	in	
gold open access by 202014.
It	is	acknowledged	that	the	shift	in	publishing	models	
will	take	time	and	that	proactive	incentives	are	required	
to help “move academic prestige to open access”15 sooner. 
Therefore, it is also essential to promote the green route 
13.	Laakso	M,	Welling	P,	Bukvova	H,	Nyman	L,	Björk	BC,	Hedlund	T.	 
The development of open access journal publishing from 1993 to 2009. 
PLoS ONE. 6(6): e20961 (2011)
14. Open Access, Editorial. Nature Materials. 11(5): 353 (2012)
15. For instance: http://techland.time.com/2012/04/26/if-harvard-cant-
afford-academic-journal-subscriptions-maybe-its-time-for-an-open-
access-model/ (26 April 2012), www.knowledge-exchange.info/Default.
aspx?ID=459 and www.guardian.co.uk/science/2012/apr/15/better-
models-for-open-access (15 April 2012)
open access and advocate for a maximum permissible 
embargo period of 6 months for the benefit of research-
ers and the public16 – bearing in mind that in any event 
both gold and green routes are complementary. 
EMRC instigated this Science Policy Briefing to 
examine whether there are new opportunities for open 
access in biomedical research within Europe that will 
benefit European biomedical researchers and European 
society as a whole. 
This briefing will first focus on the current status of 
open access in biomedical research, with sections on the 
specificities of biomedical research, the barriers to open 
access, issues relating to publishers and institutional 
repositories and a description of the international and 
European landscapes. The briefing will then present 
the	various	opinions	expressed	by	the	task	force	on	how	
best to achieve open access in biomedical research in the 
future. Finally a series of recommendations on common 
principles will be made.
16. For instance: Open Access, Editorial. Nature Materials. 11(5): 353 
(2012) and www.nature.com/authors/policies/license.html
Figure 1. The development of open access journal publishing from 1993 to 2009. Source: Laakso M et al. PLoS ONE. 6(6): e20961 (2011).  
Figure reproduced by courtesy of Mikael Laakso.
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Open access: where are we 
today in biomedical research?
The specific importance of open access 
to biomedical research
The biomedical community is attached to peer review 
and publication in high-quality journals has a central 
role in a researcher’s career. Set against this, traditional 
journal subscriptions are stretching the finances of 
universities and research institutions and cannot be 
maintained at a time of severe financial constraints in 
the public sector17. Furthermore, it is important that 
availability and accessibility are not adversely affected 
by	copyright	issues.	This	adds	to	the	pressure	to	seek	
new methods of publishing research findings in an 
openly accessible way.
For many years the biomedical field has benefited 
from PubMed, a free bibliographic database provided by 
the National Library of Medicine (NLM)18 in the US. 
Since	2000,	a	direct	link	to	full-text	articles	in	PubMed	
Central (PMC)19 has been provided. The content of PMC 
is derived from both self-archiving by researchers and 
publishers20	making	their	journal	content	available	in	
the repository (a list of participating journals is avail-
able in PMC21). The entire content of full open access 
journals is directly deposited in PMC by publishers 
immediately upon publication. There also exist a num-
ber	of	subscription-based	journals	which	make	their	full	
content available in PMC after an embargo period of 
6-12 months (see the PMC journal list). The existence of 
this	structured	international	disciplinary	archive	makes	
the biomedical field more advanced than most others; 
it has revolutionised medical publishing by radically 
changing the way research results are circulated and has 
undoubtedly facilitated biomedical research, innovation 
and discoveries.
PMC International (PMCI)22 is a collaborative effort 
between the National Institutes of Health (NIH) and 
17.	The	recent	statement	by	Harvard	University	shows	that	this	issue	even	
affects the best resourced universities. http://isites.harvard.edu/icb/icb.
do?keyword=k77982&tabgroupid=icb.tabgroup143448  
(17	April	2012)
18.	PubMed	is	linked	to	a	number	of	resources	such	as	those	of	genomics	
or proteomics. www.nlm.nih.gov/
19. PMC is the database of freely available full-text biomedical literature 
developed by the US NLM. It currently contains around 2.5 million 
articles. www.ncbi.nlm.nih.gov/pmc/
20. Publishers include commercial publishers (Elsevier, Nature Publishing 
Group,	Springer,	Wiley-Blackwell,	Wolters	Kluwer,	etc.)	and	scientific	
learned societies.
21. www.ncbi.nlm.nih.gov/pmc/journals/
22. www.ncbi.nlm.nih.gov/pmc/about/pmci/
organisations	in	others	countries	to	create	a	network	of	
digital archives. UKPMC and PMC Canada are such 
collaborative centres. There is a big push among funding 
agencies for researchers to deliver articles into reposito-
ries that can be freely accessed. This pressure is coming 
from the US23, the European Commission24 and national 
funders such as the UKPMC funders in the UK, e.g., 
Medical Research Council (MRC)25 and Wellcome 
Trust26, as well as international organisations such as 
the United Nations Educational, Scientific and Cultural 
Organisation (UNESCO)27.
Problems with access  
to health literature
Access to scientific literature has a direct impact on soci-
ety,	with	several	studies	demonstrating	a	link	between	
quality of healthcare and access to biomedical informa-
tion28.
Nevertheless, there are countless stories29 about 
researchers, practitioners, health and science policy-
makers	 and	 students	 in	 developing	 and	 developed	
countries not being able to access relevant health-
related information and being restricted to reading only 
abstracts. Paywalls30 constitute a disincentive to access 
full journal articles.
The most common barrier to accessing journal arti-
cles in both academia and industry is the requirement 
for researchers to pay for access31. In a 2006 study32, 35% 
23. www.whitehouse.gov/sites/default/files/microsites/ostp/public_
access-final.pdf
24. http://ec.europa.eu/research/science-society/open_access
25. www.mrc.ac.uk/Ourresearch/Ethicsresearchguidance/
Openaccesspublishing/index.htm and www.rcuk.ac.uk/research/Pages/
outputs.aspx 
26. www.wellcome.ac.uk/About-us/Policy/Spotlight-issues/Open-access/ 
and www.bbc.co.uk/news/science-environment-17668722
27.	www.unesco.org/new/en/communication-and-information/resources/
publications-and-communication-materials/publications/full-list/policy-
guidelines-for-the-development-and-promotion-of-open-access/
28. For example: Jennings SKG et al. The effects of on-screen, point of 
care computer reminders on processes and outcomes of care. Cochrane 
Database of Systematic Reviews, Issue 3. Art. No.: CD001096 (2009); 
McGowan J et al.	Just-in-time	information	improved	decision-making	
in	primary	care:	a	randomized	controlled	trial.	PLoS ONE.	3(11):	e3785	
(2008); Chaudhry B et al. Systematic review: impact of health information 
technology on quality, efficiency, and costs of medical care. Ann Intern 
Med. 144(10):	742-752	(2006).
29. For example: Yamey G. Excluding the poor from accessing biomedical 
literature: A rights violation that impedes global health. Health and 
Human Rights. 10(1): 21-42 (2008). www.hhrjournal.org/index.php/hhr/
article/view/20
30. Systems preventing Internet users from accessing webpage content 
without a paid subscription. http://en.wikipedia.org/wiki/Paywall
31. RIN, PRC and JISC report. Access to scholarly content: gaps and barriers 
(2011). http://rinarchive.jisc-collections.ac.uk/node/1172 
32. PRC. Journals and scientific productivity. A case study in immunology 
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of respondents said they experienced some difficulty in 
accessing all the articles they needed. Reported access 
was	 best	 in	 the	 wealthy	 English-speaking	 countries	
(US, Canada, UK, Australia), not so good in smaller 
European countries, the Middle East and Asia and even 
worse in the rest of the world.
Research and development enterprises also face barri-
ers when trying to access up-to-date quality information. 
Pay-per-view and subscriptions are the main channels, 
although access rates remain below those of large com-
panies and universities33. A 2011 study shows that almost 
80% of innovation-based small and medium enterprises 
(SMEs)	in	Denmark	have	difficulties	accessing	research	
information, which severely hampers product develop-
ment and has a significant financial impact on both the 
SMEs themselves and the economy34. Studies in the UK 
have shown that subscription access imposes consider-
able additional costs on businesses and organisations 
seeking	to	build	on	academic	research,	not	only	in	terms	
of access charges but also in terms of time spent search-
ing for ways to access articles and in duplication of 
work35,36,37. Limited access to up-to-date research thus 
has a negative impact on innovation projects. 
Important barriers to open access  
in biomedical research
Many researchers are still confused about the con-
cept of open access, with some believing that it simply 
refers to publication, which is by definition in the pub-
lic domain. Others appear to be reluctant to publish in 
open access or to place papers in their local repository. In 
the UK, for example, where APCs are often mentioned 
as a major barrier to open access, the Wellcome Trust 
and microbiology (2006). www.homepages.ucl.ac.uk/~uczciro/
prcwhitepaper.pdf
33. PRC. Access by UK small and medium-sized enterprises to professional 
and academic information (2009). www.publishingresearch.net/
SMEaccess.htm
34.	Report	on	SMEs	in	Denmark	(2011):	www.fi.dk/publikationer/2011/
adgang-til-forskningsresultater-og-teknisk-information-i-danmark	(in 
English and Danish)
35. Research report to JISC from HOST Policy Research. Benefits to the 
private sector of open access to higher education and scholarly research 
(2011). 
http://open-access.org.uk/wp-content/uploads/2011/10/OAIG_Benefits_
OA_PrivateSector.pdf 
36. Research report to JISC from the Office of Public Management and 
the National Council of Voluntary Organisations. Benefits of open access to 
scholarly research for voluntary and charitable sector organisations (2012). 
http://ie-repository.jisc.ac.uk/576/
37.	Research	report	to	JISC	from	Rightscom	Ltd	and	Matrix	Evidence	Ltd.	
Benefits of open access to scholarly research to the public sector (2012).  
http://ie-repository.jisc.ac.uk/575/
found that compliance with its open access mandate was 
only 50%, even when funds were made available for open 
access publishing. Scientists need to be given incentives 
to publish in open access and to be made much more 
aware of the use, importance and benefits of open access 
publishing.
There is still a perception amongst researchers that 
making	their	paper	openly	available	through	repositories	
will reduce their choice of journals in which to pub-
lish. This perception is hard to shift and is unfounded. 
The MRC (UK) displays on its website a list of around 
250 journals in which MRC-funded researchers publish 
most38, and most of the journals offer an open access 
option compliant with the MRC policy. 
Whilst open access publishing is more common in 
biomedical research than in other disciplines, there 
remain several barriers to the full adoption of this 
model. 
The Study of Open Access Publishing (SOAP)39 col-
lected the views of nearly 40,000 researchers on open 
access. The main reasons for authors not publishing in 
open	access	are	a	lack	of	funding	and	a	perceived	lack	of	
quality of open access journals in their field compared to 
traditional publications. 
Whilst the majority of the most popular journals 
offer an option to publish in open access, finding the 
relevant information on some journal websites is often 
difficult, or the explanation given ambiguous. This is 
particularly the case for ‘hybrid’ journals, which handle 
the open access APC publishing process in parallel with 
the traditional subscription-based model. All of this 
adds to the researcher’s administrative burden. Gold 
open access journals have much more straightforward 
processes, which are proving to be increasingly attrac-
tive to authors who want their results to be disseminated 
quickly.
The perceived costs of publishing in open access 
are	also	often	acknowledged	as	a	disincentive.	Whilst	
authors have always paid significant publication charges, 
even in the traditional subscription-based publishing 
model,	the	addition	of	$1,000	to	$5,000	(ca.	€760	to	
€3,800) per paper is perceived by many as too expensive 
and/or unaffordable. This perception is heightened by 
the fact that subscription costs, usually paid from librar-
ies’ budgets, are not so visible to them.
38. ‘MRC frequently used journals: summary of publisher open 
access policies’, last updated in July 2012. www.mrc.ac.uk/Utilities/
Documentrecord/index.htm?d=MRC007842 
39. SOAP was funded by the European Commission as a part of the 
Seventh	Research	Framework	Programme	(FP7)	–	Science	and	Society,	
and ran from March 2009 to February 2011.  
http://arxiv.org/abs/1101.5260 
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Finally, self-submission of a manuscript to a repos-
itory (see section on page 10) is often perceived as yet 
another administrative burden at the end of an already 
long publication process. 
Most biomedical research is financed by public agen-
cies, which are increasingly implementing directives and 
policies aimed at ensuring that the outputs of taxpayer-
supported research are made publicly available. Open 
access mandates by funding agencies may relate to 
articles	only	or	to	articles	and	data,	and	they	can	take	
different shapes, the most common being the deposit of 
the	final	or	author’s	version	of	work	in	a	repository,	or	the	
open access ‘paid’ option with the payment of an APC46. 
Notably, a large number of biomedical research funding 
and performing agencies have an open access policy in 
place47.	However,	researchers	still	lack	awareness	of	these	
mandates and of their requirements and conditions. The 
lack	of	consistency	in	funders’	policies	adds	to	the	con-
fusion, as research is often funded from more than one 
source.
In addition, an increasing number of universities 
in Europe have also issued open access mandates. This 
upsurge	has	sparked	a	heated	debate	amongst	some	com-
mercial publishers who consider these policies a threat 
to their income and have proposed restrictions such as 
embargo periods, APCs and licensing agreements or 
insisted that institutional libraries retain their subscrip-
tions	before	these	mandates	can	be	implemented.	The	key	
issue is to clarify whether these publishers oppose short 
embargoes	prior	to	making	these	outputs	publicly	avail-
able or whether they oppose open access mandates as 
such, which would be a head-on clash with strategies and 
policies emerging from publicly funded organisations48. 
Against	 this	 background,	 it	 is	 vital	 that	 science	
funders, research performing institutions, researchers 
and libraries redouble their efforts to ensure that the 
huge benefits that open access offers for advancing sci-
ence and innovation, and for society as a whole, can be 
realised.
The publishing business model  
and the rise of open access journals
Biomedical journals account for 59% of journals across 
all disciplines and their articles for 58% of all articles 
published. The largest publisher (measured by number 
46. www.sherpa.ac.uk/romeo/PaidOA.php?la=en&version=
47.	For	a	full	list:	www.sherpa.ac.uk/juliet/
48.	Recent	discussions	around	the	Research	Works	Act	can	be	found	at,	
for instance: http://thomas.loc.gov/cgi-bin/bdquery/z?d112:h.r.3699:
The availability of grant funding coupled with 
funders’ mandates has certainly had an impact on the 
availability of open access journals in biomedicine. A 
recent study40 of the open access journals listed in the 
Directory of Open Access Journals (DOAJ)41 (8,228 as 
of 24 September 2012) concluded that just over 100,000 
articles were published and made available to the global 
scientific community in 2010 through APC-funded 
open	access	at	an	estimated	cost	of	$91	million	(ca.	€70	
million). This figure is far below the estimated 1.5 mil-
lion articles that are published annually in English in 
science, technology and medicine journals. 
Biomedical journals also have some of the highest 
APCs of any discipline, with prices ranging from $1,500 
to $3,000 (ca. €1,130-€2,400) for full open access jour-
nals. Hybrid journals usually charge a higher APC, up 
to $5,000 for Cell (ca. €3,800) or £400 (ca. €500) per 
page for The Lancet (both published by Elsevier) with 
the most common fee being $3,000 (ca. €2,400)42. There 
is	a	risk	that	publishers	will	increase	the	price	of	APCs,	
restrict archiving in institutional repositories (IRs) and 
maintain the hybrid model, which would have a nega-
tive impact on institutions’ budgets. This strategy may 
threaten the achievement of the ultimate goal – open 
access to research outputs worldwide. Whilst the cost 
of	 knowledge	 dissemination	must	 take	 into	 account	
the wider benefits to society, research and economic 
growth, it is important to recognise that the balance 
of costs between gold and green open access will need 
to be monitored carefully in order to ensure long-term 
sustainability, particularly in research-intensive uni-
versities43. The entry of new players in the publishing 
market,	such	as	PLoS,	the	soon-to-be-launched	eLife44 or 
PeerJ45, as well as the development of new ways of com-
municating	scientific	discoveries,	are	also	likely	to	have	a	
positive impact in terms of controlling publishing costs. 
40.	Solomon	DJ	and	Björk	BC.	A study of open access journals using article 
processing charges (2012). www.openaccesspublishing.org/apc2/preprint.pdf
41. www.doaj.org
42. See reference 38
43. All universities would see savings from worldwide gold open access 
when	APCs	are	at	current	averages	(£570,	around	€730)	but	results	would	
differ if universities adopted gold open access unilaterally. In this case, the 
gold open access scenario would cost more than the present subscription-
based model whereas green open access would offer the greatest economic 
benefits to individual universities, unless additional funds are made 
available to cover gold open access costs. See full study in Swan A and 
Houghton J. Going for gold? The costs and benefits of gold open access for UK 
research institutions: further economic modelling. Report to the UK Open 
Access Implementation Group (2012). http://ie-repository.jisc.ac.uk/610/ 
44. www.elifesciences.org
45. PeerJ (http://peerj.com/) is a new initiative that aims to bring down 
costs - publishing gold open access for $99, for life. 
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of journals from all disciplines) is Elsevier, followed 
by Springer-Kluwer49,	Wiley-Blackwell	and	Taylor	&	
Francis50. Predominant publishing agreements lie at the 
heart of the current crisis of restricted access to scientific 
literature. Until recently, publishers enjoyed, in practice, 
a monopoly as they were the only conduits offering 
access to research outputs. This situation facilitated the 
implementation of an economic strategy based on price 
increases for both print and online journal subscriptions 
beyond annual inflation rates. Most journal publishing 
revenues are generated from academic library subscrip-
tions	(68-75%	of	total	revenue),	followed	by	corporate	
subscriptions	 (15-17%),	 advertising	 (4%),	membership	
fees and personal subscriptions (3%), and various author-
side payments (3%)51.
However, the Internet provides enormous possibili-
ties to researchers for enhancing the dissemination and 
re-use of research and for targeting the right audience. 
These possibilities have been embraced by some pub-
lishers, many of whom are new. The BioMed Central 
(BMC) and Public Library of Science (PLoS) journal 
series, eLife or BioResearch Open Access52, for example, 
are only available online. The role of publishers is there-
fore undergoing a dramatic transformation. While some 
have been more agile in adapting to this new environ-
ment, others have struggled to see how they can preserve 
revenues whilst shifting from a pay- at-the-point-of-pub-
lishing to a pay-at-the-point-of-reading system. At this 
juncture, critical issues need to be resolved, such as how 
to ensure the use of appropriate licensing to maximise 
re-use, while protecting authors’ right to attribution and 
devising a system for publishers to develop sustainable 
business models that support open access.
Licenses
When	talking	about	open	access	to	publications,	 it	 is	
important	to	make	a	distinction	between	the	right	to	
‘read’ and the right to ‘re-use’, sometimes expressed as 
free access vs. open access53 or ‘gratis’ vs. ‘libre’54. In the 
49. Springer Science+Business Media reached an agreement with Wolters 
Kluwer	to	acquire	the	Pharma	Marketing	and	Publishing	Services	
division in autumn 2011. www.springer.com/about+springer/media/press
releases?SGWID=0-11002-6-1293721-0
50. www.mcafee.cc/Journal/Summary.pdf (Preston McAfee, March 2012)
51. RIN report. Activities, costs and funding flows in the scholarly 
communications system (2008).  
http://rinarchive.jisc-collections.ac.uk/our-work/communicating-and-
disseminating-research/activities-costs-and-funding-flows-scholarly-
commu 
52. www.liebertpub.com/biores
53. MacCallum C. When is open access not open access? PLoS Biol. 5(10): 
e285	(2007).	www.plosbiology.org/article/info:doi/10.1371/journal.
pbio.0050285
54. Suber P. ‘Gratis and libre open access’. Scholarly Publishing and 
traditional	publishing	model,	authors	are	often	asked	to	
transfer copyright to the publishers at the time of publi-
cation55.	In	doing	so,	they	usually	forsake	their	right	to	
re-use the content of the paper without the publisher’s 
permission56.	More	often,	the	author’s	version	(unlike	the	
publisher’s version) can be self-archived after an agreed 
embargo period of usually between 6 and 12 months57. 
The Creative Commons attribution license (CC BY), 
which	allows	most	 re-use	of	work,58 ensures that the 
licensed	version	of	work	is	available	free	in	perpetuity	
and clearly stipulates the authors’ right to attribution 
and what can be done with the material after publica-
tion.
The usual perception is that, in contrast to the situa-
tion with gold open access, most articles deposited under 
green open access (see next section) are free to access but 
not to re-use. However, the boundaries are not clear. 
For instance, the 2008 Harvard open access policies59 
grant the institution a wide set of non-exclusive rights, 
and the terms of use for their repository60 grant re-use 
rights which go well beyond fair use rights61. It is the first 
adopted policy to focus on permissions rather than on 
deposits62.
It is clear from the complexity of the various licenses, 
mandates	 and	 embargo	periods	 that	 further	work	 is	
required to clarify the terms under which scientific 
research outputs are published and exactly what rights 
are transferred, licensed or retained, in order to enable 
wider	diffusion	and	re-use	of	research	papers.	A	task	
force was recently set up by the Confederation of Open 
Access Repositories with a mandate to issue further 
guidance in this domain63.
Business models
Many large commercial publishers offer APC schemes 
whereby authors can publish articles that are made 
Academic Resources Coalition (SPARC) Open Access Newsletter (August 
2008). www.earlham.edu/~peters/fos/newsletter/08-02-08.htm#gratis-
libre
55. Example of an Elsevier Transfer of Copyright Agreement: www.entcs.
org/ctf2.pdf
56. For example, Elsevier’s ‘Ways to use journal articles’: 
http://libraryconnect.elsevier.com/newsletters/supporting-
usersorganizations/2011-04/ways-use-journal-articles-published-elsevier
57.	A	list	of	publisher	copyright	and	self-archiving	policies	is	made	
available by the University of Nottingham through the Sherpa/RoMEO 
platform: www.sherpa.ac.uk/romeo 
58. http://creativecommons.org/licenses/by/3.0/deed.en
59. http://osc.hul.harvard.edu/policies 
60. http://osc.hul.harvard.edu/dash/termsofuse 
61. Suber P. SPARC Open Access Newsletter (June 2012).  
www.earlham.edu/~peters/fos/newsletter/06-02-12.htm
62. Suber P. SPARC Open Access Newsletter (March 2008).  
www.earlham.edu/~peters/fos/newsletter/03-02-08.htm
63. www.coar-repositories.org/working-groups/licenses-task-force/
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freely available upon publication64 in subscription-
based journals (the so-called hybrid open access). An 
increasing number of publishers are also launching gold 
open access titles. Some, such as Springer, embraced the 
new open access model fairly early on and developed 
new collections that are only available in open access 
(SpringerOpen) whilst accommodating funders’ man-
dates with hybrid models. Others, such as Elsevier, have 
only recently launched open access journals. Another 
open access-oriented practice observed amongst tradi-
tional publishers has been the acquisition of gold open 
access publishers (e.g., Springer’s purchase of BMC 
in 2008 and Wolters Kluwer Health’s acquisition of 
Medknow	Publications	in	2011).
However, the charging of an open access APC is seen 
by many funding organisations and research institu-
tions as a ‘double-dipping’ practice65, whereby publishers 
charge two or three times for the same content. Some 
universities even have policies that clearly state that 
money is not to be used for this purpose66. 
The benefits of depositing an article in a repository 
upon publication as an alternative are also recognised 
by research funders and institutions. These reposito-
ries include repositories hosted by institutions to which 
authors are affiliated and renowned central repositories 
of peer-reviewed articles. 
However, traditional business models of large sub-
scription-based publishers have not greatly adapted 
to the new publishing scenarios vis-à-vis institutions. 
New and sustainable business and funding models are 
required, such as that created by the Alliance of German 
Science Organisations Priority Initiative ‘Digital 
Information’67. Efforts to include open access archiving 
clauses in model licenses and negotiation guidelines are 
being made by a growing number of national consortia. 
This	new	strategy	looks	beyond	negotiations,	guarantee-
ing the greatest amount of content for the lowest price 
in order to include greater usage rights for the licensed 
content68. 
64. www.sherpa.ac.uk/romeo/PaidOA.php?la=en&version= 
65. Double dipping (see http://definitions.uslegal.com/d/double-
dipping/): practice of receiving compensation, benefits, etc. from two 
or more sources in a way regarded as unethical. For instance, publishers 
being paid by libraries for subscription-based journals and open access 
APCs.
66. A good compilation of open access funds schemes developed by 
single research institutions and universities is available from: http://oad.
simmons.edu/oadwiki/OA_journal_funds. Institutions that adhered to 
the Compact for Equity Publishing Fund (COPE) commit themselves to 
establishing a fund to pay for open access fees of gold open access journals 
only. See: www.oacompact.org/faq/#whichjournals
67.	www.allianzinitiative.de/en
68. www.coar-repositories.org/news/liber-award/ and www.coar-
repositories.org/working-groups/licenses-task-force 
Many scientific societies rely on their publications 
as	a	key	source	of	 income	and	could	be	affected	by	a	
greater move towards open access publishing. Scientific 
society journals already seem to be feeling the impact, 
most	likely	because	it	is	easier	for	libraries	to	cancel	their	
subscriptions with these societies than with big publish-
ers with whom the library may have a contract involving 
multiple titles bundled into one agreement (so-called 
‘big deals’). It is worth noting that not all scholarly socie-
ties are against open access and that the number of open 
access journals published by learned societies has grown 
by	25%	since	200769.
It is now time to reconsider the publishers’ role. 
Funders have the opportunity to redefine the services 
they need from publishers in the new electronic environ-
ment	and	to	stipulate	how	they	would	like	to	purchase	
services that are still very important to the research 
community. 
Transition to a model where instead of charging for 
access, publishers charge for services such as coordi-
nating peer review, providing brand value, formatting, 
web-hosting and archiving is now a real possibility. 
Within this context, the Publisher and Library Solutions 
group (JISC-PALS)70, through their forum for the 
development and dissemination of best practice and 
innovation, should help demonstrate the value that pub-
lishers	and	librarians	working	together	can	offer	higher	
education and beyond.
In conclusion, while there is no doubt that publishers 
can add value to scholarly publications, recent discus-
sions in the US (see section on page 13) surrounding the 
proposal	for	the	Research	Works	Act71 and the Federal 
Research Public Access Act (FRPAA)72 have highlighted 
some fundamental differences in the perception of what 
the role of publishers should be73. 
Green open access:  
the repositories approach
Repositories are commonly divided into national, insti-
tutional, or subject/disciplinary repositories. 
69. Suber P. SPARC Open Access Newsletter (December 2011). www.
earlham.edu/~peters/fos/newsletter/12-02-11.htm and www.arl.org/
sparc/publications/open-access-journals-from-society-publishers.shtml
70.	www.jisc.ac.uk/aboutus/howjiscworks/committees/workinggroups/
palsmetadatagroup.aspx
71.	http://thomas.loc.gov/cgi-bin/bdquery/z?d112:h.r.3699: 
72.	http://thomas.loc.gov/cgi-bin/bdquery/z?d112:S2096: and http://
thomas.loc.gov/cgi-bin/bdquery/z?d112:HR4004: 
73.	Full	details	of	the	discussions	in	Cameron	Neylon’s	article	(3	February	
2012): http://cameronneylon.net/blog/the-research-works-act-and-the-
breakdown-of-mutual-incomprehension/
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Green open access has been instrumental in the 
rapid increase in the free availability and readability 
of research outputs. As shown in Figure 2, open access 
repositories and their contents have grown dramatically 
since September 200474. The Directory of Open Access 
Repositories OpenDOAR75 lists 2,205 IRs worldwide 
(as of 24 September 2012). Of those with medicine and 
health outputs, 43.3% are located in Europe, 20.6% 
in the US, 18.9% in Asia, and 10.6% in South America. 
Approximately a fifth of all annual research outputs are 
made available in open access, and a large proportion 
of these outputs are hosted in repositories76, which are 
more than mere platforms providing access to data, grey 
literature and preservation services77. IRs are widespread 
and many multidisciplinary and university repositories 
house medical research outputs. 
An increasing number of research institutions and 
universities are seeing the many benefits to be gained 
from setting up their own platforms to provide open 
access to a wide variety of activity outputs, organise 
institutional and scientific material for analysis and 
internal management purposes, store and preserve 
digital assets and enhance the online visibility of their 
institution and researchers by showcasing their fields 
of excellence. The value of IRs is also being increased 
by	linking	them	into	the	Current	Research	Information	
Systems (CRIS) of universities and research institutes78.
Since the development of scientific online journals, 
long-term digital preservation of research outputs 
has become a major challenge because electronic access 
to journals and publishers’ platforms is purchased for 
only a limited period of time. The setting up of IRs ena-
bles universities, research institutions and funders to 
have a view of both their present and past output, some-
times even at a national level. 
The cost of setting up an IR can vary greatly79 but 
74.	See	‘Dramatic	growth	of	open	access’	series	in	Heather	Morrison’s	blog	
(30 June 2012). http://poeticeconomics.blogspot.com.es/search/label/
dramatic%20growth%20of%20open%20access and Bielefeld Academic 
Search Engine (BASE) statistics. http://www.base-search.net/about/en/
about_statistics.php?menu=2
75.	www.opendoar.org/
76.	SPARC	Europe.	‘A	thumbs	up	for	open	access,	but	an	expensive	way	
of getting there’ (11 July 2012). http://sparceurope.org/sparc-europe-
response-to-the-finch-report/ 
77.	Report	of	the	working	group	on	expanding	access	to	published	
research findings (Finch group report). Accessibility, sustainability, 
excellence: how to expand access to research publications (June 2012).  
www.researchinfonet.org/publish/finch 
78.	A	Current	Research	Information	System,	commonly	known	as	‘CRIS’,	is	
any informational tool dedicated to providing access to and disseminating 
research information. See: www.eurocris.org and http://sonexworkgroup.
blogspot.com/2011/08/repositories-and-cris-working-smartly.html
79.	Barton	MR	and	Walker	JH.	Building	a	business	plan	for	DSpace,	
MIT Libraries’ Digital Institutional Repository. Journal of Digital 
a recent study showed that for all the universities ana-
lysed, during a transition period when subscriptions 
are maintained, the cost of adopting green open access 
was much lower than that of gold open access, except in 
cases where additional funds were released for gold open 
access80. Large disciplinary repositories may initially 
seem to be much more expensive but they can offer sig-
nificant economies of scale. Centralising databases has 
also been shown to be highly cost-effective81. The cur-
rent cost of administering PMC ($3.5 to 4 million, ca. 
Information 4, no. 2 (2003). DSpace@MIT estimated its annual 
running costs at $285,000 (ca. €215,000). http://18.7.29.232/bitstream/
handle/1721.1/26700/Barton_2003_Building.pdf?sequence=1. See also: 
Publishing and the Ecology of European Research (PEER) Economics Report 
(2011). A survey for the Association of Research Libraries found start-up 
costs ranged from $8,000 (ca. €6,000) to $1,800,000 (ca. €1,358,000). 
The range for ongoing operations budgets for implementers is $8,600 
(ca.	€6,500)	to	$500,000	(ca.	€377,000).	www.peerproject.eu/fileadmin/
media/reports/PEER_Economics_Report.pdf
80. Swan A and Houghton J. Going for gold? The costs and benefits of 
gold open access for UK research institutions: further economic modelling. 
Report to the UK Open Access Implementation Group (2012). For all 
possible university models and open access scenarios examined, the cost 
of adopting green open access would be much lower than the cost of 
gold open access, with green open access self-archiving in parallel with 
subscription publishing costing institutions around one-tenth the amount 
that gold open access might cost. http://ie-repository.jisc.ac.uk/610/ 
81.	Kurtz	MJ,	Eichhorn	G,	Accomazzi	A,	Grant	C,	Demleitner	M	and	
Murray SS. Worldwide use and impact of the NASA Astrophysics Data 
System digital library. J. Am. Soc. Inf. Sci. Technol. 56: 36-45 (2005) or 
http://arxiv.org/pdf/0909.4786.pdf. The concept of ‘utility time’ is 
defined as a measure of how a tool improves efficiency. For a research 
tool such as the National Aeronautics and Space Administration (NASA) 
Astrophysics Data System digital library (ADS/URANIA), this is the 
amount of research (or researcher’s) time gained by using it compared 
with not using it. In 2002, the utility time of using this single, central 
searchable	access	point	amounted	to	the	equivalent	of	736	full-time	
equivalent researchers or $250 million (around €200 million) or the 
astronomical research done in France.
Figure 2. Growth of open access archives from 2004-2012. The over 
2,000 repositories contain over 36 million documents, as harvested by 
the Bielefeld Academic Search Engine (BASE). Source: http://www.base-
search.net/about/en/about_statistics.php?menu=2
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€2.6 million per annum) represents only around 1/100 
of 1% of the NIH’s $31 billion research budget for 201182.
Automated ways of feeding IRs with content are 
currently being explored, as spontaneous self-archiving 
amounts to only around 15%. The only institutions that 
consistently achieve a near-100% annual self-archiving 
rate are those that adopt a self-archiving mandate, 
put appropriate infrastructures (platforms) in place 
to support researchers through user-friendly technol-
ogy and provide relevant support from library staff83. 
For instance, the library staff at the Spanish ‘Consejo 
Superior de Investigaciones Científicas’ (CSIC) boast an 
average deposit rate of 85% in Digital.CSIC84. 
Motivating factors for self-archiving (indexation by 
Google, Google Scholar and other search engines, pro-
vision	of	usage	statistics,	research	preservation,	 links	
to authors’ CVs and higher citation rates when articles 
are available in open access) do not always outweigh the 
demotivating	factors	(technophobia,	lack	of	knowledge/
reticence over copyright issues, time consumption, fear 
of	plagiarism,	lack	of	awareness	of	benefits)85. 
Sixty-five percent of the larger scientific publish-
ers formally allow some form of self-archiving86, with 
some policies including an embargo period. Whilst large 
medicine and health publishers have until recently been 
green publishers, thus allowing the deposit of pre-print87 
and post-print88 versions by default, some have started to 
revise their position in the light of increasing numbers 
of open access mandates89. However, there is no clear 
evidence to date that large-scale, systematic depositing 
82. Committee for Economic Development report. The future of taxpayer-
funded research: who will control access to the results? (2012). www.
ced.org/images/content/issues/innovation-technology/DCCReport_
Final_2_9-12.pdf
83.	Stevan	Harnad’s	keynote	address	(18	May	2010):	 
http://openaccess.eprints.org/index.php?/archives/719-guid.html  
See also: Swan A. Open access self-archiving: an introduction (2005). http://
eprints.soton.ac.uk/261006/ and PEER Behavioural Research: authors 
and users vis-à-vis journals and repositories (2011). www.peerproject.eu/
fileadmin/media/reports/PEER_D4_final_report_29SEPT11.pdf
84. Digital.CSIC annual report (2011) available from:  
http://digital.csic.es/handle/10261/52123
85. Swan A. The open access citation advantage: studies and results to date 
(2010). http://eprints.soton.ac.uk/268516/ 
See also: http://opcit.eprints.org/oacitation-biblio.html and  
www.plosone.org/article/info:doi/10.1371/journal.pone.0013636 
86. Sherpa/RoMEO analyses: www.sherpa.ac.uk/romeo/statistics
87.	Wikipedia	definition:	“A	draft	of	a	scientific	paper	that	has	not	yet	
been published in a peer-reviewed scientific journal”.
88. Final peer-reviewed manuscript accepted for journal publication, 
including all modifications from the peer review process but not yet 
formatted by the publisher.
89.	The	Swedish	libraries	have	taken	a	public	position	disagreeing	with	
these new constraints. www.kb.se/OpenAccess_english/OA-News/
Statement-about-Elseviers--new-policy-concerning-authors-rights-to-self-
archive-articles/ (10 June 2011) and http://openaccess.kb.se/?p=637 
(31 January 2012)
of authors’ final peer-reviewed manuscripts into reposi-
tories harm publishers; there does, however, appear to 
be evidence of increased total usage through green open 
access, including usage at the publisher’s site90.
There is growing interest, mostly from institutions, 
in the inclusion of open access clauses in electronic 
resources licenses that “allow authors from authorised 
institutions, or institutions to promptly store their articles 
appearing in licensed journals generally in the form pub-
lished by the publisher in a repository of their choice and 
to make them available in open access”.91
More harmonisation and wider aggregation efforts 
are	needed	to	promote	international	networks	of	open	
scientific infrastructures and to minimise the dispersion 
of data resulting from the implementation of different 
open access policies and mandates, be they institutional, 
national or funder-based. 
The international landscape 
of open access in biomedical 
research
UNESCO
UNESCO promotes open access and has a dedicated 
Global Open Access Portal (GOAP)92 in operation since 
April 2011 that is expanding rapidly with the addition of 
new open access initiatives and projects at a global level. 
The organisation places particular emphasis on scientific 
information emanating from publicly funded research, 
and	works	with	partners	to	improve	awareness	of	the	
benefits	of	open	access	among	policy-makers,	research-
ers	and	knowledge	managers.	UNESCO	also	recently	
released its ‘Policy Guidelines for the Development and 
Promotion of Open Access’93.
90. Findings from the PEER final report (June 2012), described under the 
European Commission section on page 13. www.peerproject.eu/reports/ 
91. Knowledge Exchange report. Incorporating new developments in daily 
licensing practice: setting conditions for open access, patron driven access, 
and data and text mining (2011). http://www.knowledge-exchange.info/
Default.aspx?ID=485
92. www.unesco.org/ci/goap
93. http://unesdoc.unesco.org/images/0021/002158/215863e.pdf
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The US NIH Public Access Policy
In	2007	US	Congress	passed	a	 law	requiring	that	all	
NIH-funded manuscripts be made freely available in 
PMC no later than 12 months after publication94.
The NIH policy honours, and is consistent with, US 
copyright law. It is based on the principle that an author, 
as	the	creator	of	the	work,	holds	the	copyright	in	the	
original paper. Traditionally, authors transfer all their 
rights to the publisher when an article is accepted for 
publication	in	a	 journal.	The	NIH	policy	simply	asks	
authors to retain a small portion of these rights, allow-
ing NIH to distribute the accepted manuscript through 
the PMC system in return for the funding the authors 
receive from NIH. NIH does not claim copyright on 
the version of the paper in PMC and users of PMC are 
expected to honour any copyright that applies to the 
paper. Authors are free to publish in any journal pro-
vided that they retain the right to deposit a copy of their 
peer-reviewed manuscript in PMC, in compliance with 
the policy.
Unlike	the	Wellcome	Trust	and	other	funding	agen-
cies that have arranged with publishers to pay open 
access APCs, NIH has no such arrangements. However, 
its grants policy has long allowed its researchers to pay 
reasonable publication charges from their grant funds. 
(Even when there is no open access fee, authors some-
times have to pay page and figure charges).
PMC	contains	more	than	77,000	NIH-funded	papers	
published	in	2011	alone;	this	is	an	estimated	75%	of	all	
NIH-funded papers published that year. Interestingly, 
75%	of	all	NIH-funded	articles	published	since	mid-
2008,	when	the	mandatory	policy	first	took	effect,	are	
deposited in PMC. 
Approximately 60% of NIH-funded articles in PMC 
are deposited in the form of a final peer-reviewed manu-
script95. The remaining 40% come from publishers who 
supply the final published version of the article to PMC 
directly. Some articles come from open access publishers 
such as PLoS and BMC, but many come from traditional 
publishers	 that	allow	NIH	to	make	a	final	published	
version freely available 12 months after publication. In 
September 2012, almost 1,400 journals had agreements 
with PMC to deposit all NIH-funded articles or the 
entire contents of the journal96.
Although publishers have often stated that the NIH 
94. http://publicaccess.nih.gov/policy.htm 
95. However, this number does not correspond to all individual authors 
uploading	their	manuscripts,	since	bulk	upload	mechanisms	are	used	by	
some commercial publishers.
96. Current journal totals in:  
http://publicaccess.nih.gov/submit_process_journals.htm
policy will harm the scientific publishing industry, 
damage the peer review process and adversely affect the 
scientific quality of articles, there are no data to sup-
port these assertions. Instead, data published by the 
International Association of Scientific, Technical and 
Medical Publishers (STM)97 show continued growth in 
the industry, despite the recession98. 
Nevertheless, open access is still a topic of hot politi-
cal	debate.	The	proposed	Research	Works	Act99, which 
would have effectively repealed the NIH public access 
policy, was strongly rejected. Concerns persist that leg-
islations such as the Stop Online Piracy Act (SOPA)100 
introduced in October 2011 could significantly restrict 
the free flow of scientific information. On the oppo-
site side of the fence, in 2010, US Congress introduced 
the FRPAA101 which mandates public access 6 months 
after publication to research funded by all federal agen-
cies with annual extramural research budgets of $100 
million	(ca.	€75	million)	or	more.	In	February	2012	the	
Public Access Bill was introduced as a bipartisan legis-
lation to encourage open access to research funded by 
US federal agencies102, and the University of California, 
San	Francisco	recently	implemented	a	policy	to	make	
research papers immediately accessible to the public free 
of charge103.
The European landscape  
of open access in biomedical 
research
European Commission
The European Commission first showed interest in 
2005 with a study on the economic and technical evolu-
tion	of	scientific	publication	markets	in	Europe104. Open 
access to research results rapidly became an important 
aspect	of	 the	broader	 area	of	knowledge	 circulation,	
97.	www.stm-assoc.org/
98. www.stm-assoc.org/industry-statistics/stm-market-size-and-
growth-2006-2010/ and www.stm-assoc.org/industry-statistics/stm-
subsegment-forecast-2011-2014/
99. http://thomas.loc.gov/cgi-bin/query/z?c112:H.R.3699.IH:/ 
100. http://judiciary.house.gov/issues/issues_RogueWebsites.html
101. http://thomas.loc.gov/cgi-bin/bdquery/z?d112:S2096: and  
http://thomas.loc.gov/cgi-bin/bdquery/z?d112:HR4004:
102. www.arl.org/sparc/media/blog/FRPAA_Spotlight_New_
Bipartisan_Cosponsors.shtml 
103. http://senate.ucsf.edu/2011-2012/j-lib-openaccess.html 
104. http://ec.europa.eu/research/science-society/pdf/scientific-
publication-study_en.pdf
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which	the	Commission	undertook	to	explore	in	a	coher-
ent	way	within	 the	 Seventh	 Framework	Programme	
(FP7)	and	in	line	with	specific	statements	made	in	the	
EU communications Innovation Union105 and A Digital 
Agenda for Europe106.
Following an invitation from the Council of EU 
Research Ministers to experiment with open access, the 
Commission	 launched	the	Open	Access	Pilot	 in	FP7	
in 2008107. The pilot, which runs until the end of the 
framework	programme,	mandates	open	access	to	peer-
reviewed	articles	resulting	from	research	funded	in	7	
areas. Grant agreements contain a special clause requir-
ing beneficiaries to deposit their final published articles 
or final peer-reviewed manuscripts in an institutional or 
subject-based	repository	and	to	make	their	best	effort	
to ensure open access to these articles within a defined 
period (6-month embargo in the case of health). In addi-
tion	to	the	pilot,	FP7	rules	of	participation	also	allow	all	
projects to have open access APCs eligible for reimburse-
ment. The EU-funded portal OpenAIRE (Open Access 
Infrastructure for Research in Europe)108 has supported 
the Open Access Pilot since 2009, with mechanisms for 
the identification, deposit, access, harvest and monitor-
ing	of	FP7-funded	articles.	
In 2011, the European Commission collected 
feedback	on	 the	experiences	of	both	 the	pilot	 imple-
mentation and the reimbursement of open access 
publishing costs109.	Almost	70%	of	respondents	with	an	
opinion thought that it was better to use self-archiving 
than open access publishing to satisfy the open access 
requirements	in	FP7.	Answers	provided	important	input	
for the future of the open access policy and practices in 
Horizon	2020,	the	future	EU	framework	programme	for	
research and innovation. In its proposal for rules for the 
participation	and	dissemination	in	Horizon	2020,	the	
Commission stated that open access will be the “norm” 
for research funded through this €80 billion research 
funding programme110. The enlarged scope and new 
forms of funding as well as the need for flexibility of 
rules	in	this	area	have	been	taken	into	account.	With	
regard to dissemination through research publications, 
105. http://ec.europa.eu/research/innovation-union/pdf/innovation-
union-communication_en.pdf#view=fit&pagemode=none
106. http://eur-lex.europa.eu/LexUriServ/LexUriServ.
do?uri=COM:2010:0245:FIN:EN:PDF
107.	http://ec.europa.eu/research/science-society/document_library/
pdf_06/open-access-pilot_en.pdf
108. www.openaire.eu/
109. http://ec.europa.eu/research/science-society/document_library/
pdf_06/survey-on-open-access-in-fp7_en.pdf
110. http://news.sciencemag.org/scienceinsider/2012/05/horizon-2020-
a-80-billion-battle.html (24 May 2012) and www.timeshighereducation.
co.uk/story.asp?sectioncode=26&storycode=419949&c=1	(17	May	2012)
an open access mandate will be applied to all projects. 
On	 17	 July 2012, the European Commission 
announced its open access policy for publicly funded 
research and published its recommendations to EU 
Member States on access to and preservation of scien-
tific information111. The goal is for 60% of European 
publicly funded research articles to be available under 
open access by 2016. Both the gold and green routes are 
considered valid approaches112.
In recent years the European Commission has 
funded a number of projects with open access issues at 
their core. One of these was the eContentplus-funded 
Publishing and the Ecology of European Research 
(PEER) project113, set up to investigate the effects of the 
large-scale, systematic depositing of authors’ final peer-
reviewed manuscripts (green open access) on reader 
access, author visibility and journal viability. The PEER 
final report highlights the results of behavioural, eco-
nomics and usage research and offers reflections on open 
access scenarios with a focus on development possibili-
ties for green open access114.
European Research Council
The open access policy of the European Research 
Council (ERC) is spelled out in the ERC Scientific 
Council guidelines dated 20 June 2012, where the 
Council reaffirmed its open access policy and strongly 
encouraged	ERC-funded	researchers	to	make	their	pub-
lications publicly available in open access as soon as 
possible, and no later than 6 months after the official 
publication date of the original article, using discipline-
specific repositories. When no appropriate repository is 
available, researchers are urged to use IRs or their own 
webpages115. The recommended repository for life sci-
ences	is	UKPMC,	to	be	known	as	Europe	PMC	from	1	
November 2012 (see Box 5)116. 
111.	European	Commission	Recommendation	(17	July	2012).	http://
ec.europa.eu/research/science-society/document_library/pdf_06/
recommendation-access-and-preservation-scientific-information_
en.pdf and http://ec.europa.eu/research/science-society/index.
cfm?fuseaction=public.topic&id=1301&lang=1 
112.	European	Commission	Press	Release	(17	July	2012).	http://europa.eu/
rapid/pressReleasesAction.do?reference=IP/12/790&format=HTML&a
ged=0&language=EN&guiLanguage=en 
113. www.peerproject.eu/
114. www.peerproject.eu/reports/ (18 June 2012)
115. ERC Scientific Council. Open access guidelines for researchers funded 
by the ERC (20 June 2012). http://erc.europa.eu/sites/default/files/
document/file/open_access_policy_researchers_funded_ERC.pdf 
116. The recommended repository for Physical Sciences and Engineering 
is ArxIv, while the ERC Scientific Council is reviewing existing practices 
and open access infrastructures in Social Sciences and Humanities and 
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A recent analysis of a sample of over 600 journal arti-
cles indicated that 62% of articles from ERC projects are 
available in open access across research domains, and 
the	figure	is	close	to	70%	in	life	sciences117.
Science Europe (formerly EUROHORCs)
In 2008, the former European Heads of Research 
Councils (EUROHORCs, now regrouped under 
Science Europe118) issued a statement including a set 
of recommendations for the adoption of a minimal 
standard on open access by its 50 Member Organisations 
(research performing and funding organisations)119. A 
working	group	on	open	access	was	established	to	exam-
ine possibilities to move beyond this minimum standard 
and implement the roadmap for actions to a ‘Common 
policy on Open Access and Permanent Access to research 
data’, one of the 10 items required to build a globally 
competitive European Research Area (ERA) according 
to the EUROHORCs and ESF vision120. 
On	 17	 July	 2012,	 Science	 Europe	 signed	 a	 joint	
statement with the European Commission and other 
stakeholder	organisations	to	reaffirm	its	commitment	
to strengthening the ERA. Science Europe members 
will now develop and implement a common open access 
policy and action plan. Actions in this area include 
encouraging publishers to shift to an open access 
business	model.	Further	work	will	 involve	sharing	of	
experiences and identification of best practices in rela-
tion to author- or institution-paid publication charges, 
and examination of how best to cover the costs of open 
access publishing121.
European countries
A number of organisations in European countries have 
engaged in the open access movement since 2003 by 
will	make	recommendations	in	the	future.
117.	ERC	report.	Open access status of journal articles from ERC-funded 
projects (June 2012). http://erc.europa.eu/sites/default/files/document/
file/open_access_study_status_journal_articles_ERC_funded_projects.
pdf 
118. www.scienceeurope.org
119. www.eurohorcs.org/SiteCollectionDocuments/EUROHORCs_
Recommendations_OpenAccess_200805.pdf 
120. ESF-EUROHORCs report. The EUROHORCs and ESF vision on a 
globally competitive ERA and their road map for actions to help build it 
(June 2008). www.esf.org/publications/corporate-publications.html 
121.	Science	Europe	News	(17	July	2012).	www.scienceeurope.org/index.
php?page=news	and	Paul	Boyle’s,	President	of	Science	Europe,	speech	(17	
July 2012). www.scienceeurope.org/uploads/Public%20documents%20
and%20speeches/120717_SE_short_statement_ERA_signing.pdf 
signing the Berlin Declaration122. The Berlin Open 
Access Conference is organised every year to follow up 
on the development and implementation of open access 
initiatives in the European landscape and beyond. 
The situation in individual countries is dependent 
on the national research environment and organisation. 
Most countries have established repositories, either at 
the institutional123 or national124 level. A number of 
institutions/funders have put mandates in place125 and 
some countries/regions have issued open access laws126. 
A panorama of repositories, open access journals, poli-
cies and other initiatives for each EU Member State is 
available on the OpenAIRE website127.
The UK is a special case in terms of biomedical 
research because of UK PubMed Central (UKPMC), 
an initiative established in partnership with PMCI 
in	 January	 2007	and	built	 in	 collaboration	with	 the	
National Center for Biotechnology Information (NCBI). 
The service is now run by the European Molecular 
Biology Laboratory’s European Bioinformatics Institute 
(EMBL-EBI) in Hinxton (UK), in partnership with the 
British Library and the University of Manchester. 
UKPMC is the responsibility of the UKPMC 
Funders’ Group led by the Wellcome Trust. It is sup-
ported by 19 funders of life sciences research, including 
16 in the UK and 3 in continental Europe: the Austrian 
Science Fund (Fonds zur Förderung der wissen-
schaftlichen Forschung, FWF) (Box 4), Telethon Italy 
and the ERC128. All UKPMC funders have common 
open access principles, requiring archiving of research 
papers in UKPMC within 6 months of publication129. 
The overall infrastructure costs are shared between 
funders	on	a	scale	that	is	proportional	to	the	size	of	their	
research budgets. This set-up enables smaller funders to 
benefit from the same collective infrastructure.
122. http://oa.mpg.de/lang/en-uk/berlin-prozess/signatoren/
123. For instance: the Spanish National Research Council Digital.CSIC 
(http://digital.csic.es), the Spanish National Health Institute Carlos III 
Scientific Electronic Library Online, SciELO Spain (http://scielo.isciii.es/
scielo.php), or the Italian National Institute of Health DSpace ISS (http://
dspace.iss.it/dspace/)
124. For instance: the French HAL - Hyper Articles en Ligne (http://
hal.archives-ouvertes.fr/) or the Scientific Open Access Repository of 
Portugal RCAAP (www.rcaap.pt)
125. Some Spanish universities and Portuguese academic and research 
institutions.
126. For instance: Spain’s Law of Science, Technology and Innovation (2011). 
www.boe.es/boe/dias/2011/06/02/pdfs/BOE-A-2011-9617.pdf
127.	www.openaire.eu/en/open-access/country-information
128. http://ukpmc.ac.uk/Funders/
129. www.rcuk.ac.uk/research/Pages/outputs.aspx
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Box 4. Example of a UK PubMed 
Central (UKPMC) European funder:  
the Austrian Science Fund (FWF)
The Austrian Science Fund (FWF) has an open 
access policy which covers all disciplines130. The 
FWF joined UK PubMed Central (UKPMC) in 
March 2010. UKPMC guidelines were developed 
for Principal Investigators (PIs) funded by the 
FWF131. Now, around 3,000 papers with FWF 
acknowledgement	are	deposited	in	PMC.	The	com-
pliance rate of the FWF is one of the highest of all 
UKPMC funders. In addition to a reminder system 
developed with UKPMC and advice offered to PIs, 
this high rate is attributable to 3 factors132. First, 
publication costs for FWF projects are not budg-
eted within a project but are covered by extra funds 
provided by the FWF for up to 3 years after conclu-
sion of the project. Second, the FWF covers costs 
for publishing in both gold open access journals and 
the so-called hybrid journals offered by some pub-
lishers.	Third,	for	Wiley-Blackwell	and	Elsevier133 
publication costs are transferred directly from the 
FWF to the publishers, with no charge payable by 
authors. Although this procedure incurs high costs, 
it	makes	it	much	easier	for	PIs	to	use	FWF	funding	
and deposit papers in UKPMC.
UKPMC provides access to over 2 million full-text 
articles, supplemented with over 26 million abstracts 
from PubMed, Agricola and the European Patent Office. 
Figure 3 below shows the number of articles available 
in UKPMC compared to the number of abstracts in 
PubMed. In 2010, around 40% of the UKPMC content 
was open access134.
The UKPMC infrastructure includes a manuscript 
submission service that allows users to self-archive 
articles in green open access, as well as a database of 
grant information that covers about 18,000 princi-
pal investigators and 35,000 grants, and enables the 
130. www.fwf.ac.at/en/public_relations/oai/index.html and position 
paper ‘Free research needs the free circulation of ideas’ (2011). www.fwf.
ac.at/en/public_relations/oai/free-research-needs-the-free-circulation-of-
ideas.html
131. www.fwf.ac.at/de/public_relations/oai/pubmed.pdf
132. www.fwf.ac.at/en/projects/peer-reviewed_publications.html
133. FWF is currently preparing an agreement with the American 
Chemical Society.
134. ‘Open access’ means ‘free to read and free to re-use’, at least for non-
commercial purposes, although all the content of UKPMC is free to read. 
http://ukpmc.blogspot.co.uk/2012/05/increasing-proportion-of-ukpmc-
articles.html
acknowledgement	of	funding	streams	associated	with	
specific research outputs, thus paving the way for com-
prehensive funding analysis.
Publishers can deposit final-version content in 
PMC – which is then mirrored in UKPMC – directly 
on behalf of authors following the gold open access 
route. This helps significantly towards compliance with 
funders’ mandates. 
UKPMC provides multiple benefits to authors and 
users. While the full-text content base of UKPMC is 
identical to that of the US PMC, the UKPMC website 
and grant reporting applications are developed indepen-
dently, which has enabled the development of additional 
research tools135. Moreover, further developments in 
text mining technology using UKPMC content are 
underway136. UKPMC gives greater visibility to authors’ 
research findings137 and allows powerful searches (e.g., 
for abstracts, full-text articles).
Diverging opinions  
on how best to achieve 
open access in biomedical 
research
There	 are	 divergent	 opinions	 amongst	 stakeholders	
on the best way to achieve free access to literature and 
on what would be a fair and sustainable model for the 
future. Two different views are expressed in the boxes 
below. The first (Box 5) supports the expansion of 
Europe PMC (now cofunded by the ERC) to a Europe-
wide repository in biomedicine, while recognising the 
challenges and barriers to this expansion. The second 
(Box 6) advocates equal support of the gold and green 
routes to open access publishing in order to achieve what 
is	best	for	biomedical	research	science.	Other	stakehold-
ers	think	that	the	ultimate	goal	to	achieve	is	gold	open	
access but mechanisms to control costs will need to be 
put in place to ensure that this route remains affordable 
and sustainable for authors and their organisations as 
well as for publishers.
135. For example, connecting datasets such as the protein database 
SwissProt with full-text articles.
136. http://ukpmc.blogspot.co.uk/2012/07/announcing-uk-pubmed-
central-web.html 
137.	It	provides	one	portal	for	finding	both	abstracts	and	full-text	
articles,	and,	furthermore,	links	this	content	with	underlying	biomedical	
databases.
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Box 5. From UK PubMed Central (UKPMC) to Europe PMC as the future European 
repository in biomedicine?
On 13 July 2012, the European Research Council 
(ERC) renewed its commitment to open access by 
announcing that it would join the 18 already existing 
funders and participate in the UKPMC open access 
repository service138. The ERC became the third 
non-UK funder to join UKPMC, following Telethon 
Italy and the Austrian Science Fund (FWF) (Box 4). 
In recognition of the extended reach of UKPMC, 
the funders have agreed to rebrand the service and 
UKPMC will become Europe PubMed Central 
(Europe PMC) as of 1 November 2012. 
The	ERC	statement	confirmed	that	a	key	aim	of	
this initiative was to “extend the repository further 
and encourage other European funders of life sciences 
research	 to	make	 the	outputs	of	 the	 research	 they	
fund freely available through Europe PMC”.
Europe PMC will maintain all the existing fea-
tures of the current UKPMC, including a single 
point of access for all PubMed and PMC content, 
but it will also open up the opportunity for outputs 
138. http://erc.europa.eu/sites/default/files/press_release/files/
EuropePMC_press_release_WT_ERC_FINAL.pdf
from ERC-funded research to be retrieved from the 
most commonly used life sciences literature databases 
across the world. Standard repository functionalities, 
such as manuscript submission, search options and 
citation rates, will be complemented by the unique 
ability to automatically identify terms of interest (e.g., 
genes, proteins, species and diseases) in abstracts and 
full-text articles. 
Whilst the benefits of a single point of access for 
all	life	sciences	literature	are	acknowledged	by	most,	
a number of challenges have been identified and will 
need	 to	 be	 taken	 into	 consideration	 in	 extending	
Europe PMC to new participants.
•		In some jurisdictions, mandating deposition in an 
archive is difficult or in some cases even impossible 
(due	to	the	fact	that	the	copyright	owner	of	the	work	
is the researcher and not the employer), and further 
work	might	be	 required	 to	encourage	authors	 to	
deposit their articles. An unambiguous open access 
policy is essential for all Europe PMC funders, not 
only to ensure that researchers are clear about their 
responsibilities but also to ensure a good return on
•••
Figure 3. Year-on-year growth in availability of full-text articles in UKPMC and proportion of those that are open access in comparison to the number of 
abstracts available in PubMed. Of the 925,000 articles indexed by PubMed in 2010, UKPMC was about 18% of the size of PubMed and around 7% of UKPMC 
articles were open access vs. PubMed content. Read-only articles: green; open access articles: blue. Figure reproduced by courtesy of Jo McEntyre.  
Source: http://ukpmc.blogspot.co.uk/2012/01/open-access-ukpmc-and-pubmed-how-are-we.html
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Box 6. Gold and green routes to open 
access publishing should be equally 
supported
The green route should be recognised as a valuable 
route to achieve open access in which European 
partners have invested. Many research organisa-
tions are in favour of equally supporting the green 
and the gold open access publishing routes, and 
existing mandates are overwhelmingly focused 
on the provision of open access via repositories. 
Mandating the deposit of authors’ copies of arti-
cles in an open access repository is the preferred 
policy option for the European Commission, the 
European Research Council and over 100 other 
European institutions.
•••
the necessary investment made in the repository. 
Whilst a harmonised implementation of the Europe 
PMC funders’ mandate would be desirable, it is not a 
prerequisite to any given organisation participating.
•	 In order to maximise the benefits of research and 
accelerate new discoveries, the aim of Europe PMC 
is	to	make	literature	available	as	quickly	and	widely	
as possible and in any case within 6 months of the 
publication date. In some instances, the only way to 
achieve this is by paying article processing charges 
(APCs) to the publishers and Europe PMC par-
ticipants would need to plan for these costs as an 
integral part of the research process and ensure that 
funding and processes are in place to manage APCs.
•		All Europe PMC funders participate in the run-
ning and development costs of the repository, which 
come in addition to the funding of APCs. In order to 
help manage this within all types of organisations, 
small or large, individual contributions are capped
for the duration of the programme and are scaled 
proportionally to the biomedical research budget of 
each participant (each organisation’s contribution 
also diminishes as new participants join). In return 
for their yearly contribution, new participants get 
access to a fully functioning system and related sup-
port services, as well as the opportunity to influence 
further developments.
•		Europe PMC is not currently set up to harvest papers 
from other repositories, which could be problematic 
for	institutions	that	would	like	to	participate	but	
have already developed institutional repositories.
These are real barriers to a wider adoption of Europe 
PMC as the main central repository providing free 
access to all European life sciences research articles, 
and	a	closer	collaboration	between	all	kinds	of	research	
organisations is needed to build further this service.
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Recommendations
The	task	force	involved	in	this	Science	Policy	Briefing	
agreed on a common set of principles. Therefore, EMRC 
strongly supports the following recommendations, sum-
marised	in	Box	7:
Recommendation 1  
There is a moral imperative for open access
Research papers should be made freely available to all 
to	read,	use	and	re-use,	with	appropriate	acknowledge-
ment, in order to maximise the value of biomedical 
research,	build	on	the	body	of	knowledge,	accelerate	the	
process of discovery and improve human health.
Recommendation 2 
Individual agencies must work together  
to raise awareness of the moral imperative  
for open access
Agencies and organisations that fund and perform 
research,	libraries,	publishers	and	researchers	must	work	
in concert to raise awareness of the moral imperative 
for open access publishing. Enhanced efforts towards 
national, European and international partnerships are 
the basis for the successful achievement of open access 
to research outputs.
Concrete actions needed from individual agencies
R2.1. Funders should adopt a clear statement in favour 
of open access, provide a mechanism for funding gold 
open access and employ clear and binding mandates 
for	green	open	access.	They	should	encourage	and	work	
towards enabling gold open access publication and at the 
same time mandate green open access with an embargo 
period of no more than 6 months. Gold open access 
APCs should be based on an affordable, sustainable 
model and be monitored and recorded.
R2.2. Research performing organisations and fund-
ing	bodies	need	 to	give	 scientists	 incentives	 to	make	
their research outputs available in open access and raise 
awareness among researchers about the use, importance 
and moral imperative of open access, whilst adhering to 
the	principle	that	it	is	the	intrinsic	merit	of	the	work,	and	
not	the	title	of	the	journal	in	which	an	author’s	work	is	
published,	that	should	be	considered	in	making	funding	
decisions139.
R2.3. Funders should challenge all players in the 
scholarly communication system (publishers, learned 
societies, academia) to change the current model so that 
139. Wellcome Trust’s principle
it serves the needs of the research community better 
than it does at the moment. 
R2.4. Funders need to find ways together with research 
institutions, research libraries and publishers to redirect 
substantial parts of the existing subscription budgets 
to pay for APCs. There are already examples in other 
research fields such as SCOAP3 140.
R2.5.	Measures	should	be	taken	to	ensure	that	funded	
authors	keep	the	necessary	rights	which	allow	the	re-use	
of their research.
140. Consortium that facilitates open access publishing in High Energy 
Physics by re-directing subscription money: http://scoap3.org
Box 7. Summary of recommendations
1. There is a moral imperative for open access
Research papers should be made freely available 
to all to read, use and re-use, with appropriate 
acknowledgement,	in	order	to	maximise	the	value	
of biomedical research, build on the body of 
knowledge,	accelerate	the	process	of	discovery	and	
improve human health.
2. Individual agencies must work together to raise 
awareness of the moral imperative for open access
Agencies and organisations that fund and perform 
research, libraries, publishers and researchers must 
work	 in	 concert	 to	 raise	 awareness	 of	 the	moral	
imperative for open access publishing. National, 
European and international partnerships are the 
basis for the successful achievement of open access 
to research outputs. Specific actions that differ-
ent	agencies	need	to	undertake	in	order	to	move	
towards open access have been outlined.
3. All research stakeholders should work together 
to support the extension of Europe PubMed Central 
(Europe PMC) into a Europe-wide PMC
In order to facilitate discoveries and innovation in 
biomedical	research,	research	stakeholders	should	
collaborate to establish a Europe-wide repository 
in biomedicine as a partner site to the US equiva-
lent PMC. The recently rebranded Europe PMC 
represents a valuable means to achieving this goal, 
provided that the diversity of European partners’ 
mandates and policies can be integrated.
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Recommendation 3
All research stakeholders should work  
together in order to support the extension  
of Europe PubMed Central (Europe PMC) into  
a Europe-wide PMC
R3.1. The adoption of a Europe-wide repository in bio-
medicine is recommended to facilitate discoveries and 
innovation in biomedical research, the use and re-use of 
research publications and the potential use of advanced 
text mining technology.
R3.2. All	research	stakeholders	should	collaborate	to	
establish this Europe-wide repository as a partner site to 
the US equivalent PMC.
R3.3. The recent rebranding of UKPMC to Europe PMC 
represents a valuable means to achieving this goal, pro-
vided that solutions can be found in order to incorporate 
the current diversity of European partners’ mandates 
and policies. 
Conclusions
The turnover of information in biomedical sciences is 
fast, so rapid delivery of information is needed at a fair 
price.
Current journal subscription rates are not affordable 
for universities and research institutions. It is recognised 
that publishers offer a service that needs to be paid for 
– but only at a price that the community can afford. 
Mechanisms to control the costs of gold open access will 
need to be put in place, so that this route remains afford-
able and sustainable for authors and their organisations 
as well as for publishers.
The ideal situation is that all research papers be made 
freely available to read, use and re-use. For this, there 
are two complementary routes, the gold route to open 
access publishing with reasonable APCs and the green 
route with a maximum permissible embargo period of 
6 months.
Individual researchers should be made aware that 
they need to engage with IRs and that open access 
mandates need to be fulfilled. There are examples of 
successful approaches, such as the Open Repository and 
Bibliography	(ORBi)	linked	to	the	research	assessment	
exercise system of the University of Liège in Belgium141, 
which demonstrate what can be achieved with strong 
institutional commitment and leadership. 
PMC is an extremely valuable tool for researchers 
141. http://orbi.ulg.ac.be/?locale=en
and there would be merit to support the programme to 
extend the newly rebranded Europe PMC. PMC has a 
stated commitment to increasing its international reach 
so Europe PMC would chime with this. However, there 
are a number of challenges for such a move, in particu-
lar for those institutions/agencies that already have a 
repository.
In conclusion, EMRC supports the gold route to open 
access publishing as the ultimate goal to maximise the 
discoverability, access and re-use of biomedical research 
in Europe wherever it is funded or performed but under 
the condition that APCs are both affordable and sus-
tainable.	It	is	acknowledged,	however,	that	this	will	take	
time. Therefore, it is essential to promote the green route 
open access and advocate for a maximum permissible 
embargo period of 6 months for the benefit of research-
ers and the public – bearing in mind that in any event 
the gold and green routes are complementary.
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Useful websites
All websites mentioned in this Science 
Policy Briefing were last accessed on 24 
September 2012.
Directory of Open Access Journals 
(DOAJ): www.doaj.org
Directory of Open Access Repositories 
(OpenDOAR): www.opendoar.org
Registry of Open Access Repositories 
(ROAR): http://roar.eprints.org
Registry of open access repository 
material archiving policies:  
www.eprints.org/openaccess/
policysignup/
Research funders’ guidelines, mandates 
and policies: www.sherpa.ac.uk/juliet/
index.php
Publishers’ and journals’ policies:  
www.sherpa.ac.uk/romeo/
Abbreviations 
APC: Article Processing Charge
AVČR: Academy of Sciences of the 
Czech	Republic
BASE: Bielefeld Academic Search 
Engine
BMC: BioMed Central
CC: Creative Commons
CERN: European	Organization	 
for Nuclear Research
COPE: Compact for Equity Publishing 
Fund
CRIS: Current Research Information 
Systems
CSIC: Consejo Superior de 
Investigaciones Científicas (Spanish 
National Research Council)
DFG: Deutsche Forschungsgemeinschaft 
(German Research Foundation)
DOAJ: Directory of Open Access 
Journals
EACR: European Association for 
Cancer Research
EBI: European Bioinformatics Institute
EMBL: European Molecular Biology 
Laboratory
EMRC: European Medical Research 
Councils
ERA: European Research Area
ERC: European Research Council
ESF: European Science Foundation
EU: European Union
EUROHORCs: European Heads of 
Research Councils
Europe PMC: Europe PubMed Central
FCCN: Fundação para a Computação 
Científica Nacional (Portuguese 
Foundation for National Scientific 
Computing)
FECYT: Fundación Española para 
la Ciencia y la Tecnología (Spanish 
Foundation for Science and 
Technology)
FP7: Seventh	Research	Framework	
Programme
FRPAA: Federal Research Public  
Access Act
FWF: Fonds	zur	Förderung	der	
wissenschaftlichen Forschung (Austrian 
Science Fund)
FWO: Fonds	voor	Wetenschappelijk	
Onderzoek	–	Vlaanderen	(Research	
Foundation – Flanders)
GAČR: Czech	Science	Foundation
GOAP: Global Open Access Portal 
(UNESCO)
HAL: Hyper Articles en Ligne (French 
repository)
Inserm: Institut National de la Santé 
et de la Recherche Médicale (French 
National Institute of Health and 
Medical Research)
IR: Institutional Repository
ISCIII: Instituto de Salud Carlos III 
(Spanish National Health Institute 
Carlos III)
ISS: Istituto Superiore di Sanità (Italian 
National Institute of Health)
JISC: Joint Information Systems 
Committee
LIBER: Association of European 
Research Libraries
MRC: Medical Research Council (UK)
NASA: National Aeronautics and Space 
Administration
NCBI: National Center for 
Biotechnology Information
NIH: National Institutes of Health
NLM: National Library of Medicine
OpenAIRE: Open Access Infrastructure 
for Research in Europe
OpenDOAR: Directory of Open Access 
Repositories
ORBi: Open Repository and 
Bibliography
PALS: Publisher and Librarians 
Solutions group
PEER: Publishing and the Ecology of 
European Research
PIs: Principal Investigators
PLoS: Public Library of Science
PMC: PubMed Central
PMCI: PubMed Central International
PRC: Publishing Research Consortium
RCAAP: Repositório Científico de 
Acesso Aberto de Portugal (Scientific 
Open Access Repository of Portugal)
RIN:	Research	Information	Network
ROAR: Registry of Open Access 
Repositories
SciELO: Scientific Electronic Library 
Online
SMEs: Small and Medium Enterprises
SOAP: Study of Open Access Publishing
SOPA: Stop Online Piracy Act
SPARC: Scholarly Publishing and 
Academic Resources Coalition 
STM: International Association of 
Scientific, Technical and Medical 
Publishers
UKPMC: UK PubMed Central
UNESCO: United Nations Educational, 
Scientific and Cultural Organisation
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